The Effects of Bupropion on Negative Symptoms in Schizophrenia

authors:

avatar Mojtaba Yassini a , avatar Neda Shariat a , avatar Mohammad Nadi a , avatar Fariba Amini a , avatar Mohammad Vafaee b

Shahid Sadughi University of Medical Siences, Yazd, Iran.
Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Warning: No corresponding author defined!
Iranian Journal of Pharmaceutical Research : IJPR: Vol.13, issue 4; 1227-1233
article type: Original Article
received: March , 2013
accepted: November , 2013
DOI: https://doi.org/10.22037/ijpr.2014.1568

how to cite: Yassini M, Shariat N, Nadi M, Amini F, Vafaee M. The Effects of Bupropion on Negative Symptoms in Schizophrenia. Iran J Pharm Res. 2014;13(4):e125587. https://doi.org/10.22037/ijpr.2014.1568.

Abstract

This study was designed determine the efficacy of bupropion versus placebo in subjects with negative symptoms of schizophrenia.
A convenience sample of 40 patients of both genders aged 18-60 years who were living in psychiatric care centers were randomly treated with bupropion (started with 75 mg twice a day; increased to 100 mg thrice daily) or placebo. The diagnosis of schizophrenia was confirmed by a psychiatrist based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria. Before and after the intervention, severity of negative symptoms was determined using a reliable and valid Persian version of Scales for the Assessment of Negative Symptoms (SANS).
Comparison of post-treatment total SANS score and subscale scores between bupropion treated patients and placebo group demonstrated no significant difference. Moreover, comparison of pre- treatment and post-treatment total SANS score and subscales within 2 groups revealed that nor bupropion neither placebo improved the severity of negative symptoms significantly.
Present study demonstrated that bupropion has no significant effect on SANS score of patients with severe negative symptoms. However, further studies with larger sample size are recommended to achieve more accurate results.

Introduction

The relative absence of a group of psychological experiences and social interactions in patients with schizophrenia is termed negative symptoms (1).

These symptoms are very common, and include anergia, apathy, affective flattening, alogia and social withdrawal (2-5). Previous studies have demonstrated significant relationships between negative symptoms and poor premorbid function, lowered IQ, and poor clinical outcome (3, 6-11).

Since the negative symptoms of schizophrenia impair social and occupational activities (12, 13), the persistence of these symptoms disproportionately limits a patient›s recovery and functions (14, 15). For this reason, increased attention has been given to the treatment of negative symptoms recently (16).

Although antipsychotic medications are very effective in the treatment of positive symptoms of schizophrenia, negative symptoms are generally poorly responsive to these drugs (17). Therefore, the successful treatment of negative symptoms still remains an important challenge for clinical psychiatrists (18).

There is increasing evidence on an integrative approach to the pathophysiology of schizophrenia that combines different neurotransmitter systems (19). Based on this evidence, several studies have investigated the role of co-administration of antipsychotics and other psychotherapeutic drugs in the treatment of schizophrenia especially in patients with negative symptoms (17, 20). Various classes of psychotherapeutic medications including antidepressants, buspirone, psychostimulants, anticholinergics or alpha 2 blocking agents have been used to augment the effects of antipsychotic medications in patients with negative symptoms (21-25). However, the results have been contradictory in terms of clinical efficacy (17).

Bupropion is a strong norepinephrine and dopamine reuptake inhibitor, as well as a nicotinic receptor antagonist. It has been widely prescribed as an atypical antidepressant and a smoking cessation aid. In addition, some studies have investigated the impact of bupropion prescription on negative symptoms of schizophrenia; however, they have reported inconsistent results about its effectiveness (26-28, 37).

In light of the above, this comparative study was designed determine the efficacy of bupropion versus placebo in subjects with negative symptoms of schizophrenia.

Experimental

Study population and design:

After approval of the study by the ethic committee of Shahid Sadoughi University of Medical Sciences (project number :XXXX ) and obtaining informed consent, this double-blind, placebo controlled, randomized clinical trial was performed on patients with chronic schizophrenia who were living in psychiatric care centers. This investigation was performed in Yazd, Iran, between March 2011 and December 2012.

Inclusion criteria were: Patients aged 18-60 who had a history of schizophrenia for at least 2 years, and were treated with a constant dose of typical or atypical antipsychotic agent over 1 month prior to the study were considered eligible. The diagnosis of schizophrenia was confirmed by a psychiatrist based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria.

Patients with other psychiatric comorbidities -such as mania, major depressive disorder or suicidal tendencies-,patients with organic brain disorders or mental retardation, patient who had any contraindication for bupropion, pregnant women and breastfeeding mothers, alcoholic or drug abuse patients and patients with epilepsy or other significant medical diseases were excluded.

After initial evaluation of 75 patients, a convenience sample of 40 patients of both genders who met the study criteria were entered the study. Using simple randomization, patients were randomly allocated into 2 treatment groups (Figure 1).

Study flow patients, psychiatrists and other study staff were blinded to the treatment assignment

Study flow patients, psychiatrists and other study staff were blinded to the treatment assignment

Figure 1

Therapeutic regimens

Patients in the bupropion group (20 participants) were commenced on an initial dose of 75 mg twice a day for the first 3 days, followed by 100 mg thrice a day. In the placebo group (20 participants), an identical placebo tablet was added to their daily medications. Both bupropion and placebo were administered orally.

Data collection and follow-up

A reliable and valid Persian version of Scales for the Assessment of Negative Symptoms (SANS) was used to assess the severity of patients’ negative symptoms before the intervention. Using this scale, the severity of negative symptoms including affective flattening or blunting, alogia, avolition-apathy, anhedonia-asociality and attention was evaluated by a psychiatrist.

All assessments were conducted on a six-point scale (from 0: no symptom to 5: very severe symptom), and a total SANS score and 5 subscale scores were determined. During the first month of the investigation, patients were visited every week; then, every month for 2 months. After 12 weeks of treatment, the SANS score was re-calculated. All 40 participants completed the study. None of patients developed major adverse effects such as acute psychosis after bupropion therapy or significant change in sleep pattern.

Statistical analysis

Data were analyzed by the Statistical Package for the Social Sciences (SPSS) 20.0 (SPSS Inc., Chicago, IL, USA). Independent

t-test, paired t-test and Chi-square were used when appropriate. p-values less than 0.05 were considered statistically significant.

Results

There was no significant difference between 2 groups regarding baseline data (Table 1).

Comparison of post-treatment total SANS score and subscale scores between bupropion treated patients and placebo group demonstrated no significant difference. Moreover, comparison of pre- treatment and post-treatment total SANS score and subscales within 2 groups revealed that nor bupropion neither placebo improved the severity of negative symptoms significantly (Table 2).

Table 1

Baseline characteristics of two groups

Bupropion (N:20)Placebo (N:20)Total(N:40)p-value
Age (year)49.58 ± 12.0549.00 ± 9.4549.23 ± 10.370.88
Sex (male/female)13/712/825/150.69
Duration of schizophrenia (year)22.25 ± 12.1323.71 ± 8.9722.97 ± 10.070.71
SANS scoreTotal 100.08 ± 11.3396.11 ± 14.2897.30 ± 13.560.11
Affect 27.08 ± 3.8027.50 ± 4.0727.33 ± 3.900.78
Alogia 20.83 ± 4.6818.72 ± 3.5119.56 ± 4.080.17
Avolition 17.16 ± 1.5215.77 ± 3.5516.23 ± 3.110.23
Anhedonia23.58 ± 1.7821.44 ± 3.4322.30 ± 3.040.12
Attention 13.33 ± 2.1011.55 ± 3.6112.26 ± 3.180.13
Table 2

Comparison of pre and post-treatment SANS score (total and subscales) between and within 2 groups

Pre-treatmentPost-treatmentp-value
SANS scoreTotalPlacebo(N:20)96.11 ± 14.2895.66 ± 13.700.76
Bupropion(N:20)100.08 ± 11.33100.67 ± 12.230.83
p-value0.110.31
AffectPlacebo(N:20)27.50 ± 4.0726.61 ± 3.410.35
Bupropion(N:20)27.08 ± 3.8026.83 ± 4.010.27
p-value0.780.87
AlogiaPlacebo(N:20)18.72 ± 3.5118.44 ± 3.160.33
Bupropion(N:20)20.83 ± 4.6819.58 ± 4.500.10
p-value0.170.42
AvolitionPlacebo(N:20)15.77 ± 3.5516.01 ± 3.490.40
Bupropion(N:20)17.16 ± 1.5217.19 ± 1.230.91
p-value0.230.48
AnhedoniaPlacebo(N:20)21.44 ± 3.4321.12 ± 4.730.87
Bupropion(N:20)23.58 ± 1.7823.50 ± 1.450.84
p-value0.120.17
AttentionPlacebo(N:20)11.55 ± 3.6111.44 ± 3.770.60
Bupropion(N:20)13.33 ± 2.1013.50 ± 2.390.74
p-value0.130.10

Discussion

Schizophrenia is a chronic debilitating mental illness that consists of severe disturbances in thoughts, cognitions, mood, perceptions, and relationships with others (29). Based on the nature of symptoms, the hallmark symptoms of schizophrenia are mainly categorized into positive symptoms -such as delusions, paranoia, hallucinations and disorganized thoughts- and negative symptoms -including poor motivation, lack of emotional expression, and inability to form appropriate social relationships (28). Negative symptoms are resistant to antipsychotic therapy (30), and have potential impacts on functional outcomes (16). For this reason, various medications have been evaluated to augment the effects of antipsychotic drugs on negative symptoms. It is a common clinical strategy to add antidepressants to the routine antipsychotic regimen of patients with persisting negative symptoms. However, there is still controversy regarding the effectiveness of this method.

Considering the nicotinic receptor antagonist properties of bupropion, it has been widely prescribed for patients with schizophrenia as an aid to smoking cessation (28, 31-34). Meanwhile, there has been a question that whether bupropion can improve negative symptoms by its antidepressant effect or not. However, answers to this question are inconsistent.

This clinical trial demonstrated that adding bupropion to the routine antipsychotic regimen of patients with schizophrenia does not cause any significant improvement of negative symptoms. The effects of bupropion on either total SANS score or subscale scores were not significantly different from those of placebo.

A previous study by Evins et al. evaluated the effects of a bupropion (300 mg daily) on smoking cessation of patients with schizophrenia. Meanwhile, they compared bupropion with placebo regarding their effects on negative symptoms (35). They found that bupropion-treated patients had a trend for mean SANS score to decrease from baseline to week 12; however, it was not statistically significant.

George et al. also conducted a placebo-controlled trial, and investigated effects of bupropion on smoking cessation and negative symptoms of schizophrenia. Similar to what we have found, they found that bupropion was not significantly more effective than placebo in the treatment of negative symptoms (36).

On the contrary, Rezaee and colleagues performed a placebo-controlled trial of bupropion for improving the positive and negative symptoms of schizophrenia, and demonstrated that bupropion can improve negative symptoms significantly (28).

Another pilot study reported significant improvement of SANS score after smoking cessation treatment with bupropion (32).

Comparing with the present study, subjects of these 2 studies had significantly lower mean of baseline SANS score (37.9 (32) and 11.67 (28) versus 97.30). This difference may be due the different study designs. While the main goal of this study was to evaluate the effectiveness of bupropion in the treatment of negative symptoms, previous studies were aimed to determine the efficacy bupropion in smoking cessation. Therefore, they did not primarily focus on the severity of negative symptoms. In addition, in order to have close supervision on patients regarding taking medications regularly, this study was performed on patients who were living in the psychiatric care centers who have more severe mental disorders.

Although Eden Evis et al. excluded patients with depression (32), Rezaee et al. did not consider depression as an exclusion criterion (28). Therefore, the improvement that they have observed could be indirectly caused by antidepressant effects of bupropion on concurrent depression. When patients with depressive disorders are not excluded, and both positive and negative symptoms are investigated, it is unclear whether the effect of bupropion on the negative symptoms is not merely secondary to the reduction of depression or of positive symptoms (23).

Limitations

This study was performed on a relatively small sample size. Comparing with previous studies, our patients were suffering from more severe mental disorder that may be a probable cause for failure of treatment.

In summary, we conclude that bupropion has no significant effect on SANS score of patients with severe negative symptoms. However, further studies with larger sample size are recommended to achieve more accurate results. Moreover, given these differences and in order to avoid probable effects of negative symptom severity, it would be helpful to re-evaluate effects of bupropion after grouping patients according to the severity of negative symptoms.

References

  • 1.

    Lysaker PH, Vohs JL, Tsai J. Negative symptoms and concordant impairments in attention in schizophrenia: associations with social functioning, hope, self-esteem and internalized stigma. Schizophr. Res. 2009;110:165-172. [PubMed ID: 19230622].

  • 2.

    Möller HJ. Clinical evaluation of negative symptoms in schizophrenia. Eur. Psychiatr. 2007;22:380-386.

  • 3.

    Barr MS, Farzan F, Tran LC, Fitzgerald PB, Daskalakis ZJ. A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimul. 2012;5:337-346. [PubMed ID: 21782542].

  • 4.

    Ananth J, Djenderdjian A, Shamasunder P, Costa J, Herrera J, Sramek J. Negative symptoms: psychopathological models. J. Psychiatry Neurosci. 1991;16:12-18. [PubMed ID: 2049366].

  • 5.

    Andreasen NC, Olsen S. Negative v positive schizophrenia: Definition and validation. Arch. Gen. Psychiatry. 1982;39:789-794. [PubMed ID: 7165478].

  • 6.

    Anthony WA, Jansen MA. Predicting the vocational capacity of the chronically mentally ill. Am. Psychol. 1984;39:537-544. [PubMed ID: 6742594].

  • 7.

    Bowen L, Wallace CJ, Glynn SM, Nuechterlein KH, Lutzker JR, Kuehnel TG. Schizophrenic individuals› cognitive functioning and performance in interpersonal interactions and skills training procedures. J. Psychiatr. Res. 1994;28:289-301. [PubMed ID: 7932288].

  • 8.

    Crow TJ. Brain changes and negative symptoms in schizophrenia. Psychopathol. 1995;28:18-21.

  • 9.

    Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am. J. Psychiatry. 1994;151:351-356. [PubMed ID: 7906493].

  • 10.

    Gasquet I, Haro JM, Novick D, Edgell ET, Kennedy L, Lepine JP. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int. Clin. Psychopharmacol. 2005;20:199-205. [PubMed ID: 15933480].

  • 11.

    Tamminga CA, Buchanan RW, Gold JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int. Clin. Psychopharmacol. 1998;13:21-26.

  • 12.

    Ross CA, Margolis RL, Reading SAJ, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron. 2006;52:139-153. [PubMed ID: 17015232].

  • 13.

    Biedermann F, Fleischhacker WW. Emerging drugs for schizophrenia. Expert. Opin. Emerg. Drugs. 2011;16:271-282. [PubMed ID: 21563991].

  • 14.

    Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull. 2007;33:1120-1130. [PubMed ID: 17641146].

  • 15.

    Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-219. [PubMed ID: 16481659].

  • 16.

    Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137:147-150. [PubMed ID: 22316568].

  • 17.

    Iancu I, Tschernihovsky E, Bodner E, Piconne AS, Lowengrub K. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. Psychiatry Res. 2010;179:19-23. [PubMed ID: 20472299].

  • 18.

    Carpenter WT. Clinical constructs and therapeutic discovery. Schizophr. Res. 2004;72:69-73. [PubMed ID: 15531408].

  • 19.

    Kondziella D, Brenner E, Eyjolfsson EM, Sonnewald U. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia? Neurochem Int. 2007;50:291-301. [PubMed ID: 17084946].

  • 20.

    Dell›aversano C, Tomasetti C, Iasevoli F, de Bartolomeis A. Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders. Brain Res. Bull. 2009;79:123-129. [PubMed ID: 19189858].

  • 21.

    Makinen J, Miettunen J, Isohanni M, Koponen H. Negative symptoms in schizophrenia: a review. Nordic. J. Psychiatry. 2008;27:1-8.

  • 22.

    Ames D, Marder SR, Wirshing WC. The long-term treatment of schizophrenic disorders. Bailliere›s Clin. Psychiatry. 1995;1:511-532.

  • 23.

    Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res. 2005;80:85-97. [PubMed ID: 16183258].

  • 24.

    Silver H, Nassar A, Aharon N, Kaplan A. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. Int. Clin. Psychopharmacol. 2003;18:87-92. [PubMed ID: 12598819].

  • 25.

    Jockers-Scherübl MC, Bauer A, Godemann F, Reischies FM, Selig F, Schlattmann P. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int. Clin. Psychopharmacol. 2005;20:27-31. [PubMed ID: 15602113].

  • 26.

    Weiner E BP, Summerfelt A, Gold J, Buchanan RW. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am. J. Psychiatry. 2001;158:635-637. [PubMed ID: 11282701].

  • 27.

    George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol. Psychiatry. 2002;52:53-61. [PubMed ID: 12079730].

  • 28.

    Rezaee OSM, Akbarpour F. A placebo-controlled trial of bupropion for improving the positive and negative symptoms of schizophrenia. Int. J. Collaborative Res. Int. Med. Public Health. 2012;4:1223-1230.

  • 29.

    Salokangas RKR. Medical problems in schizophrenia patients living in the community (alternative facilities). Curr. Opin. Psychiatry. 2007;20:402-405. [PubMed ID: 17551357].

  • 30.

    Stauffer VL, Song G, Kinon BJ, Ascher-Svanum H, Chen L, Feldman PD, Conley RR. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Schizophr. Res. 2012;134:195-201. [PubMed ID: 22019076].

  • 31.

    Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J. Clin. Psychopharmacol. 2007;27:380-386. [PubMed ID: 17632223].

  • 32.

    Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob. Res. 2001;3:397-403. [PubMed ID: 11694208].

  • 33.

    Haggstram FM, Chatkin JM, Sussenbach-Vaz E, Cesari DH, Fam CF, Fritscher CC. A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. Pulm. Pharmacol. Ther. 2006;19:205-209. [PubMed ID: 16517193].

  • 34.

    Tonstad S. Use of sustained-release bupropion in specific patient populations for smoking cessation. Drugs. 2002;62:37-43. [PubMed ID: 12109934].

  • 35.

    Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, Henderson DC, Schoenfeld DA, Goff DC, Rigotti NA. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J. Clin. Psychopharmacol. 2005;25:218-225. [PubMed ID: 15876899].

  • 36.

    George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, Creeden CL, Potenza MN, Feingold A, Jatlow PI. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol. Psychiatry. 2008;63:1092-1096. [PubMed ID: 18096137].

  • 37.

    Xiongjun Q, Jijun S, Hongchang Y, Yi H, Xiaofeng P, Ren-ai X. Evaluation of CYP2C9 activity in rats:Use of tolbutamide alone and in combined with bupropion. Iran. J. Pharm. Res. 2014;13:635-639. [PubMed ID: 25237359].